3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
44
Neoplasm Metastasis
5
Ovarian Neoplasms
2
Neoplasms, Hormone-Dependent
2
Carcinoma, Lobular
2
Carcinoma, Ductal, Breast
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Medullary cystic kidney disease 1
1
Lymphoma, Non-Hodgkin
1
Leiomyosarcoma
1
Hormone-sensitive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Ductal
1
Breast Neoplasms, Male
1
Breast Neoplasm Malignant Female
1
Breast Diseases
1
Breast Cancer Metastatic
1
Interventions
Fulvestrant
2
tusamitamab ravtansine
1
palbociclib
1
nirogacestat
1
exemestane
1
Tamoxifen
1
Letrozole
1
Gemcitabine
1
Docetaxel
1
Capecitabine
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Breast Cancer Metastatic
×
Letrozole
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts